GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » Degree of Operating Leverage

ELVN (Enliven Therapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Enliven Therapeutics does not have enough data to calculate Degree of Operating Leverage.


Enliven Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Enliven Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics Degree of Operating Leverage Chart

Enliven Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
- - - - -

Enliven Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enliven Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Enliven Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enliven Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Enliven Therapeutics's Degree of Operating Leverage falls into.


;
;

Enliven Therapeutics Degree of Operating Leverage Calculation

Enliven Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -110.26 (Mar. 2025) / -93.098 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=0.1843/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Enliven Therapeutics  (NAS:ELVN) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Enliven Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Enliven Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Executives
Benjamin Hohl officer: Chief Financial Officer 6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz director, officer: President and CEO ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos director, officer: Chief Scientific Officer 6200 LOOKOUT ROAD, BOULDER CO 80301
Anish Patel officer: Chief Operating Officer C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman director 5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Rahul D. Ballal director, officer: President & CEO 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Mika K Derynck director C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107